CFO Richard J. Wanstall resigns effective May 6, 2022 for other opportunity

Rein Therapeutics, Inc.

Richard J. Wanstall, CFO and principal accounting officer, resigns effective May 6, 2022 to pursue another career opportunity.
Resignation not due to any disagreement with the company on operations, policies, or practices.
Aileron has initiated a search for a new CFO.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Richard J. Wanstall

Chief Financial Officer

RNTX · Rein Therapeutics, Inc.

Effective: 2022-05-06
Filed: April 29, 2022, 7:59 PM ET

On April 25, 2022, Richard J. Wanstall, Chief Financial Officer, principal financial officer and principal accounting officer of Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), notified the Company of his resignation, effective May 6, 2022, to pursue another career opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Richard J. Wanstall resigned as Chief Financial Officer at Rein Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On April 25, 2022, Richard J. Wanstall, Chief Financial Officer, principal financial officer and principal accounting officer of Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), notified the Company of his resignation, effective May 6, 2022, to pursue another career opportunity.

View on SEC.gov

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-134322

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.